EUVIMEDEUVIMED entdecken
Open Access

Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor

Tao Zhang iD, Xinrui Ma iD, Muyun Xu iD, Jinghua Cai, Jianhua Cai, Yanguang Cao, Zhihao Zhang, Xin Ji, Jian He, German Oscar Fonseca Cabrera, Xuedan Wu iD, Weiling Zhao und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06754-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Tao Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Cha…. Hauptthemen laut MEDLINE: Receptors, Neurotensin, Copper Radioisotopes, Chelating Agents, Radiopharmaceuticals. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, NeurotensinCopper RadioisotopesChelating AgentsRadiopharmaceuticalsAnimalsMiceTissue DistributionCell Line, TumorHumansLung NeoplasmsPositron Emission Tomography Computed TomographyIsotope Labeling

Stichwörter der Autor:innen

Copper-64Lung cancerNeurotensin receptor 1 (NTSR1)Positron emission tomography (PET)Radiotheranostics

Substanzen

Receptors, NeurotensinCopper RadioisotopesChelating AgentsRadiopharmaceuticalsCopper-64

Autor:innen und Institutionen

  • Department of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina , 27599, USA. zhangtaocjh@njmu.edu.cn.
  • Department of Radiopharmaceuticals, Nuclear Medicine Clinical Transformation Center, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China. zhangtaocjh@njmu.edu.cn.
  • Department of Nuclear Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China. zhangtaocjh@njmu.edu.cn.
  • Department of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina , 27599, USA.
  • Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, Raleigh, NC, North Carolina State University, NC 27599, USA.
  • Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

ORCID-Profile: Tao Zhang, Xinrui Ma, Muyun Xu, Xuedan Wu, Zhanhong Wu, Jin Xie, Zibo Li

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Zhang, T., Ma, X., Xu, M., Cai, J., Cai, J., Cao, Y., Zhang, Z., Ji, X., He, J., Cabrera, G. O. F., Wu, X., Zhao, W., Wu, Z., Xie, J., & Li, Z. (2024). Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06754-2

Vancouver

Zhang T, Ma X, Xu M, Cai J, Cai J, Cao Y, et al. Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06754-2

BibTeX
@article{Zhang2024,
  author = {Zhang, Tao and Ma, Xinrui and Xu, Muyun and Cai, Jinghua and Cai, Jianhua and Cao, Yanguang and Zhang, Zhihao and Ji, Xin and He, Jian and Cabrera, German Oscar Fonseca and Wu, Xuedan and Zhao, Weiling and Wu, Zhanhong and Xie, Jin and Li, Zibo},
  title = {Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06754-2}
}
Kostenlos starten →